![Omeros Corporation](/common/images/company/N_OMER.png)
Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injec... Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders. Show more
Β β Newly Completed Sensitivity Analyses Demonstrate Robustness of Previously Announced Survival Superiority Over External Control in Patients with TA-TMA β Sensitivity analyses support the...
Primary statistical analysis of overall survival compared TA-TMA patients treated with narsoplimab in its pivotal trial to a cohort of over 100 TA-TMA patients not treated with narsoplimab in an...
-- Clinical Trial and Clinical Pharmacology Data Support Upcoming Enrollment of Omerosβ Zaltenibart Phase 3 Clinical Program in PNH -- Omeros Corporation (Nasdaq: OMER) today announced that two...
-- Presentations Highlight Progress in Late-Stage Development of Lead MASP-3 Inhibitor Zaltenibart -- Omeros Corporation (Nasdaq: OMER) today announced that two abstracts directed to zaltenibart...
Omeros Corporation (Nasdaq: OMER) today announced an update on its progress toward planned resubmission of its biologics license application (βBLAβ) for narsoplimab, the companyβs first-in-class...
β Conference Call Today at 4:30 p.m. ET Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.22 | 2.47747747748 | 8.88 | 9.24 | 8.28 | 371783 | 8.80736851 | CS |
4 | -1.11 | -10.8716944172 | 10.21 | 10.27 | 8.16 | 533893 | 8.97045086 | CS |
12 | 4.81 | 112.121212121 | 4.29 | 13.6 | 4.175 | 1197314 | 9.05657299 | CS |
26 | 4.77 | 110.161662818 | 4.33 | 13.6 | 3.54 | 667942 | 7.93087587 | CS |
52 | 5.75 | 171.641791045 | 3.35 | 13.6 | 2.839 | 536508 | 6.45783755 | CS |
156 | 2.99 | 48.9361702128 | 6.11 | 13.6 | 0.92 | 691899 | 4.55743019 | CS |
260 | -4.35 | -32.3420074349 | 13.45 | 25.49 | 0.92 | 769861 | 8.46387097 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.